Principles of Medical Oncology

  • Dietmar P. Berger
  • Hartmut Henß
  • Uwe Martens
  • Hartmut Bertz
  • Monika Engelhardt
  • Sebastian Fetscher


Acute Myeloid Leukemia National Cancer Institute Familial Adenomatous Polyposis Eastern Cooperative Oncology Group Endometrial Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Cancer Society. Cancer Facts and Figures 2003. Atlanta, GA, 2003Google Scholar
  2. 2.
    Jemal A, Siegel R., Ward E et al. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43–66PubMedGoogle Scholar
  3. 3.
    Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer. N Engl J Med 2000;343:78–85PubMedCrossRefGoogle Scholar
  4. 4.
    Kamangar F, Dores GM, Anderson WF. Patterns of Cancer incidence, mortality, and prevalence across five continents. J Clin Oncol 2006;24:2137–50.PubMedCrossRefGoogle Scholar
  5. 1. American Cancer SocietyGoogle Scholar
  6. 2. Intl. Association of Cancer RegistriesGoogle Scholar
  7. 3. NCI SEER DatabaseGoogle Scholar
  8. 1.
    Bergen AW, Caporaso N. Cigarette smoking. J Natl Cancer Inst 1999;91:1365–75PubMedCrossRefGoogle Scholar
  9. 2.
    Berrington de Gonzales A, Darby S. Risk of cancer from diagnostic X-rays. Lancet 2004;363:345–51CrossRefGoogle Scholar
  10. 3.
    Hahn WC, Weinberg RA. Rules for making tumor cells. N Eng J Med 2002;347:1593–603CrossRefGoogle Scholar
  11. 4.
    Jordan CT, Guzman ML, Noble M. Cancer stem cell. N Engl J Med 2006;355:1253–61PubMedCrossRefGoogle Scholar
  12. 5.
    Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer. N Eng J Med 2000;343:78–85CrossRefGoogle Scholar
  13. 6.
    Ponder BAJ. Cancer genetics. Nature 2001;411:336–41PubMedCrossRefGoogle Scholar
  14. 7.
    Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99PubMedCrossRefGoogle Scholar
  15. 8.
    World Health Organisation IARC monographs on the evaluation of carcinogenic risks to humans, 1–74. Lyon, IARC, 1972-2000Google Scholar
  16. 1. Intl. Agency for Research on CancerGoogle Scholar
  17. 2. Chemical Carcinogen InformationGoogle Scholar
  18. 3. NIH Report on CarcinogensGoogle Scholar
  19. 4. Carcinogenic Potency DatabaseGoogle Scholar
  20. 5. Cancer Genetics, NIHGoogle Scholar
  21. 6. Cytogenetics AtlasGoogle Scholar
  22. 7. Journal of CarcinogenesisGoogle Scholar
  23. 8. A subway map to cancerGoogle Scholar
  24. 1.
    Akashi K, Traver D, Kondo M et al. Lymphoid development from hematopoietic stem cells. Int J Hematol 1999;69:217–26PubMedGoogle Scholar
  25. 2.
    Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Hematol Oncol Clin North Am 2000;14:45–61PubMedCrossRefGoogle Scholar
  26. 3.
    Broxmeyer HE, Kim CH. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Exp Hematol 1999;27:1113–23PubMedCrossRefGoogle Scholar
  27. 4.
    Fey MF. Normal and malignant hematopoiesis. Ann Oncol 2007;18(suppl. 1):i9–i13PubMedCrossRefGoogle Scholar
  28. 5.
    Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532–42PubMedCrossRefGoogle Scholar
  29. 6.
    Hoang T. The origin of hematopoietic cell type diversity. Oncogene 2004;23:7188–98PubMedCrossRefGoogle Scholar
  30. 7.
    Kondo M, Wagers AJ, Manz MG et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003;21:759–806PubMedCrossRefGoogle Scholar
  31. 8.
    Kyba M, Daley GQ. Hematopoiesis from embryonic stem cells: lessons from and for ontogeny. Exp Hematol 2003;31:994–1006PubMedGoogle Scholar
  32. 9.
    LeBien TW. Fates of human B-cell precursors. Blood 2000;96:9–23PubMedGoogle Scholar
  33. 1. American Society of Hematology (ASH)Google Scholar
  34. 2. Hematological Education and NewsGoogle Scholar
  35. 3. Hematology Atlas of the University of NagoyaGoogle Scholar
  36. 4. Hematology AtlasGoogle Scholar
  37. 1.
    Boyle P, Autier P, Bartelink H et al. European Code Against Cancer and scientific justification: third version (2003). Ann Oncol 2003;14:973–1005PubMedCrossRefGoogle Scholar
  38. 2.
    Chlebowski RT, Col N et al. ASCO Technology Assessment of Pharmacology Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifen and Aromatase Inhibition. J Clin Oncol 2002;20:3328–43PubMedCrossRefGoogle Scholar
  39. 3.
    Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003;348:879–80PubMedCrossRefGoogle Scholar
  40. 4.
    Jordan VC. Chemoprevention of breast cancer with selective oestrogenreceptor modulators. Nat Rev Cancer 2007,7:46–53PubMedCrossRefGoogle Scholar
  41. 5.
    Key TJ, Allen NE et al. The effect of diet on risk of cancer. Lancet 2002;360:861–68PubMedCrossRefGoogle Scholar
  42. 6.
    Koutsky LA, Ault KA et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–51PubMedCrossRefGoogle Scholar
  43. 7.
    Kushi LH, Byers T, Doyle C et al. ACS Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical Activity. CA Cancer J Clin 2006;56:254–81 PubMedGoogle Scholar
  44. 8.
    Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the US, 2007: A review of current guidelines, practies, and prospects. CA Cancer J Clin 2007;57:90–104PubMedGoogle Scholar
  45. 1. Cancer Prevention FoundationGoogle Scholar
  46. 2. Cancer Detection and PreventionGoogle Scholar
  47. 3. National Cancer Prevention FundGoogle Scholar
  48. 4. Cancer Prevention CoalitionGoogle Scholar
  49. 5. Division of Cancer Prevention (NCI)Google Scholar
  50. 6. Center for Disease Control (CDC)Google Scholar
  51. 1.
    WHO. International Classification of Diseases, 10th edn (ICD-10). WHO, Genf, 1996Google Scholar
  52. 2.
    WHO. ICD-0 International Classification of Diseases for Oncology, 3rd edn. WHO, Genf, 2000Google Scholar
  53. 1. World Health Organization (WHO)Google Scholar
  54. 2. National Center for Health Statistics (NCHS)Google Scholar
  55. 3.
    Center for Disease Control (CDC)Google Scholar
  56. 1.
    Greene FL, Page DL, Fleming ID et al. (eds) AJCC Cancer Staging Handbook. TNM Classification of Malignant Tumors, 6th edn. Springer, New York, 2002Google Scholar
  57. 2.
    Gospodarowicz MK, Miller D, Groome PA et al. The process for continuous improvement of the TNM classification. Cancer 2004;100:1–5PubMedCrossRefGoogle Scholar
  58. 3.
    Sobin LH, Wittekind C (eds). TNM Classification of Malignant Tumors, 6th edn. Wiley, New York, 2002Google Scholar
  59. 4.
    WHO. International Classification of Diseases, 10th edn (ICD-10). WHO, Genf, 1996Google Scholar
  60. 1. American Joint Committee on Cancer (AJCC)Google Scholar
  61. 2. National Cancer Institute (NCI), with CancernetGoogle Scholar
  62. 3. Union Internationale Contre le Cancer (UICC)Google Scholar
  63. 1.
    Julia H, Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Onc 2006;24:5101–4CrossRefGoogle Scholar
  64. 1. ACS, Clinical Practice GuidelinesGoogle Scholar
  65. 2. National Guideline Clearinghouse (NGC)Google Scholar
  66. 3. National Cancer Institute (NCI), with CancernetGoogle Scholar
  67. 4. Center for Evidence-Based MedicineGoogle Scholar
  68. 1.
    Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135–41PubMedCrossRefGoogle Scholar
  69. 2.
    Garman KS, Cohen HJ. Functional status and the elderly patient. Crit Rev Oncol Hematol 2002;43:191–298PubMedCrossRefGoogle Scholar
  70. 3.
    Mor V, Laliberte L, Morris JN et al. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002–7PubMedCrossRefGoogle Scholar
  71. 4.
    Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55PubMedCrossRefGoogle Scholar
  72. 1. World Health Organization (WHO)Google Scholar
  73. 2. Eastern Cooperative Oncology Group (ECOG)Google Scholar
  74. 3. Food and Drug Administration (FDA) Oncology ToolsGoogle Scholar
  75. 1.
    Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239–53PubMedCrossRefGoogle Scholar
  76. 2.
    Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006;24:3245–51PubMedCrossRefGoogle Scholar
  77. 3.
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16PubMedCrossRefGoogle Scholar
  78. 4.
    WHO. WHO handbook for reporting results of cancer treatment. WHO, 1979Google Scholar
  79. 1. World Health Organization (WHO)Google Scholar
  80. 2. NCI, RECIST CriteriaGoogle Scholar
  81. 3. Southwest Oncology Group (SWOG)Google Scholar
  82. 1.
    Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109–17PubMedCrossRefGoogle Scholar
  83. 2.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, management. Lancet 2000;356:1255–9PubMedCrossRefGoogle Scholar
  84. 3.
    Hesslewood SR. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 1999. Eur J Nucl Med 2001;28:2–8Google Scholar
  85. 4.
    Pirmohamed M, Breckenridge AM, Kitteringham NR et al. Adverse drug reactions. BMJ 1998;316:1295–8PubMedGoogle Scholar
  86. 5.
    Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–81PubMedCrossRefGoogle Scholar
  87. 6.
    Vincent C. Understanding and responding to adverse events. N Engl J Med 2003;348:1051–6PubMedCrossRefGoogle Scholar
  88. 1. NCI Common Toxicity CriteriaGoogle Scholar
  89. 2. ECOG Common Toxicity CriteriaGoogle Scholar
  90. 3. FDA, Common Toxicity CriteriaGoogle Scholar
  91. 1.
    de Haes J, Curran D, Young T et al. Quality of life evaluation in oncological clinical trials – the EORTC model. Eur J Cancer 2000;36:821–5PubMedCrossRefGoogle Scholar
  92. 2.
    Giesler RB, Williams SD. Opportunities and challenges: assessing quality of life in clinical trials. J Natl Cancer Inst 1998;90:1498–9PubMedCrossRefGoogle Scholar
  93. 3.
    Holzner B, Bode RK, Hahn EA et al. Equating EORTC QLQ–C30 and FACT–G scores and its use in oncological research. Eur J Cancer 2006;42:3169–77PubMedCrossRefGoogle Scholar
  94. 1. Food and Drug Administration (FDA)Google Scholar
  95. 2. National Cancer Institute (NCI)Google Scholar
  96. 3. European Organization for Research and Treatment of Cancer (EORTC), “Quality of Life Web Site”Google Scholar
  97. 4. International Society for Quality of Life ResearchGoogle Scholar
  98. 1.
    Ayanian JZ, Crischilles EA, Wallace RB et al. Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol 2004;22:2992–6PubMedCrossRefGoogle Scholar
  99. 2.
    Ray-Coquard I, Philip T, de Laroche G et al. A controlled before-after study: impact of a clinical guidelines program and regional cancer network organization on medical practice. Br J Cancer 2002;86:313–21PubMedCrossRefGoogle Scholar
  100. 3.
    Schneider EC, Epstein AM, Malin JL et al. Developing a system to assess the quality of cancer care: ASCO’s National Initiative on Cancer Care Quality. J Clin Oncol 2004;22:2985–91PubMedCrossRefGoogle Scholar
  101. 4.
    Vardy J, Tannock IF. Quality of cancer care. Ann Oncol 2004;15:1001–6PubMedCrossRefGoogle Scholar
  102. 1. Evidence-Based Medicine, OxfordGoogle Scholar
  103. 2. National Guideline Clearinghouse (NGC)Google Scholar
  104. 3. Cochrane Library, Reviews for EBMGoogle Scholar
  105. 1.
    Casali P, Licitra L, Tondini C et al. START: a European state-of-the-art on-line instrument for clinical oncologists. Ann Oncol 1999;10:769–73PubMedCrossRefGoogle Scholar
  106. 2.
    Eysenbach G. The impact of the internet on treatment outcomes. CA Cancer J Clin 2003;53:355–71CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Dietmar P. Berger
    • 1
  • Hartmut Henß
    • 1
  • Uwe Martens
    • 1
  • Hartmut Bertz
    • 2
  • Monika Engelhardt
    • 1
  • Sebastian Fetscher
    • 3
  1. 1.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  2. 2.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  3. 3.Klinik für Hämatologie/Onkologie, Städt. Krankenhaus SüdSana Kliniken LübeckLübeckGermany

Personalised recommendations